转录组分类器模型在乌干达脓毒症前瞻性研究中识别高风险内型
这项在乌干达公共转诊医院开展的前瞻性队列研究纳入128例疑似脓毒症成人患者,应用源自高收入国家的19基因和7基因分类器(SepstratifieR)分配脓毒症反应特征(SRS)。19基因分类器将30例(23.4%)归为SRS-1、92例(71.9%)归为SRS-2、6例(4.7%)归为SRS-3;SRS-1以促炎性先天免疫激活及自然杀伤细胞、T细胞和B细胞免疫抑制为生物学特征,且80.0%(24/30)为晚期免疫抑制的HIV感染者。30天死亡率按内型显著不同,SRS-1最高(48.1%)。19基因与7基因SRS分配一致性差(Cohen kappa 0.11),7基因分类器分层欠佳,归为SRS-3者中15.1%(8/53)在30天死亡。
要点
- 在乌干达128例疑似脓毒症成人中,19基因分类器分配SRS-1 30例(23.4%)、SRS-2 92例(71.9%)、SRS-3 6例(4.7%)。
- SRS-1患者30天死亡率最高(48.1%),且80.0%(24/30)为晚期免疫抑制的HIV感染者,常合并结核。
- SRS-1以促炎性先天免疫激活及自然杀伤细胞、T细胞、B细胞免疫抑制为特征;SRS-2为先天免疫激活减弱、淋巴细胞免疫保留、皮质类固醇转录反应抑制。
- 19基因与7基因分类器的SRS分配一致性差(Cohen kappa 0.11),7基因分类器分层欠佳,SRS-3中15.1%(8/53)30天死亡。
- 高收入国家衍生的脓毒症内型与撒哈拉以南非洲患者共享生物学和临床特征,但宿主-病原体谱存在重大差异。
适用人群与场景
- 乌干达公共转诊医院住院的成人(n=128)疑似脓毒症患者。
- 研究未报告排除标准。
诊断标准与关键阈值
- 使用全血RNA测序数据,应用高收入国家衍生并验证的19基因和7基因分类器(SepstratifieR)将患者分配至三种脓毒症反应特征(SRS)之一。
- SRS-1由促炎性先天免疫激活及自然杀伤细胞、T细胞和B细胞免疫抑制定义;SRS-2由先天免疫激活减弱、淋巴细胞免疫保留及皮质类固醇转录反应抑制定义;SRS-3设计用于捕获转录上最接近健康的个体。
红旗征与不能漏的情况
- SRS-1患者30天死亡率最高(48.1%),且该组80.0%(24/30)为晚期免疫抑制的HIV感染者并频繁合并结核。
研究设计与关键结果
- 研究类型:前瞻性队列研究;地点:乌干达公共转诊医院;人群:成人(n=128)住院疑似脓毒症患者;干预:无。
- 19基因分类器分配:SRS-1 30例(23.4%)、SRS-2 92例(71.9%)、SRS-3 6例(4.7%)。
- 30天死亡率按内型显著不同,SRS-1最高(48.1%)。
- SRS-1患者 predominantly(80.0% [24/30])为晚期免疫抑制的HIV感染者,且频繁合并结核。
- 19基因与7基因SRS分配一致性差(Cohen kappa 0.11);7基因分类器分层欠佳,归为SRS-3者中15.1%(8/53)在30天死亡。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐;作者认为研究结果强调了背景特异性脓毒症内型分析的重要性、危重症保守生物学特征在不同场景间的可推广性,以及在低收入和中等收入国家开发更多基于病理生物学的脓毒症治疗策略的机会。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: In high-income countries (HICs), sepsis endotypes defined by distinct pathobiological mechanisms, mortality risks, and responses to corticosteroid treatment have been identified using blood transcriptomics. The generalizability of these endotypes to low-income and middle-income countries (LMICs), where the global sepsis burden is concentrated, is unknown. We sought to determine the prevalence, prognostic relevance, and immunopathological features of HIC-derived transcriptomic sepsis endotypes in sub-Saharan Africa.
DESIGN: Prospective cohort study.
SETTING: Public referral hospital in Uganda.
PATIENTS: Adults ( n = 128) hospitalized with suspected sepsis.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: Using whole-blood RNA sequencing data, we applied 19-gene and 7-gene classifiers derived and validated in HICs (SepstratifieR) to assign patients to one of three sepsis response signatures (SRS). The 19-gene classifier assigned 30 (23.4%), 92 (71.9%), and 6 (4.7%) patients to SRS-1, SRS-2, and SRS-3, respectively, the latter of which is designed to capture individuals transcriptionally closest to health. SRS-1 was defined biologically by proinflammatory innate immune activation and suppressed natural killer-cell, T-cell, and B-cell immunity, whereas SRS-2 was characterized by dampened innate immune activation, preserved lymphocyte immunity, and suppressed transcriptional responses to corticosteroids. Patients assigned to SRS-1 were predominantly (80.0% [24/30]) persons living with HIV with advanced immunosuppression and frequent tuberculosis. Mortality at 30-days differed significantly by endotype and was highest (48.1%) in SRS-1. Agreement between 19-gene and 7-gene SRS assignments was poor (Cohen's kappa 0.11). Patient stratification was suboptimal using the 7-gene classifier with 15.1% (8/53) of individuals assigned to SRS-3 deceased at 30-days.
CONCLUSIONS: Sepsis endotypes derived in HICs share biological and clinical features with those identified in sub-Saharan Africa, with major differences in host-pathogen profiles. Our findings highlight the importance of context-specific sepsis endotyping, the generalizability of conserved biological signatures of critical illness across disparate settings, and opportunities to develop more pathobiologically informed sepsis treatment strategies in LMICs.
参考来源
- Cummings MJ, Bakamutumaho B, Tomoiaga AS, et al. A Transcriptomic Classifier Model Identifies High-Risk Endotypes in a Prospective Study of Sepsis in Uganda. Crit Care Med. 2023. PMID: 37548511. doi:10.1097/CCM.0000000000006023
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。